Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DDB1 | Q16531 | 1/20 | 0.57 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.57 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CCNC | P24863 | 1/20 | 0.47 |
| ▸ | CDK8 | P49336 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121174 | 0.87 | DDB1 (0.57) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL25326690 | 0.86 | DDB1 (0.43) | DDB1CRBNGPR119 | |
| SCHEMBL2575742 | 0.86 | DDB1 (0.56) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL15470639 | 0.86 | DDB1 (0.56) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL1427617 | 0.86 | DDB1 (0.56) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL520714 | 0.86 | DDB1 (0.56) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL12968055 | 0.86 | DDB1 (0.56) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL29249379 | 0.86 | DDB1 (0.56) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL15464664 | 0.85 | DDB1 (0.55) | DDB1CRBNGPR119HPGDCCNC | |
| SCHEMBL15309800 | 0.85 | DDB1 (0.55) | DDB1CRBNGPR119CCNCCDK8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2025-07-24 | — | — | US | disclosed |
| WO-2025106910-A1 | DEGRADER MOLECULES TARGETING ANDROGEN RECEPTOR | FLARE THERAPEUTICS INC. (US) | 2025-05-22 | — | — | WO | disclosed |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | BEIGENE, LTD. (KY) | 2025-01-14 | — | — | US | disclosed |
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2024-09-26 | — | — | US | disclosed |
| CN-118344342-A | Substituted polyaromatic ring derivatives, compositions and uses thereof | 康迈迪森(北京)医药科技有限公司 | 2024-07-16 | — | — | CN | disclosed |
| CN-117624131-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| CN-117624130-A | 3- [ (1H-pyrazol-4-yl) oxy ] pyrazin-2-amine compounds as HPK1 inhibitors and uses thereof | 百济神州有限公司 | 2024-03-01 | — | — | CN | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | BEIGENE, LTD. (KY) | 2023-11-23 | — | — | US | disclosed |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-11-08 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994562-B2 | Histone demethylase inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2018-06-12 | — | — | US | disclosed |
| EP-2970211-B1 | HISTONE DEMETHYLASE INHIBITORS | QUANTICEL PHARMACEUTICALS INC (US) | 2017-07-26 | — | — | EP | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | CELGENE QUANTICEL RESEARCH, INC | 2016-02-11 | — | — | US | disclosed |
| EP-2970211-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals Inc (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014151106-A1 | HISTONE DEMETHYLASE INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2014-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240317714-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | DDB1 1570/4885CRBN 2883/4885GPR119 413/4885 |
| US-20180319793-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | DDB1 341/4885CRBN 377/4885GPR119 2359/4885 |
| US-20160039808-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM1A, KDM5C | DDB1 341/4885CRBN 377/4885GPR119 2359/4885 |
| US-20230373963-A1 | 3-[(1H-PYRAZOL-R-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | DDB1 1570/4885CRBN 2883/4885GPR119 413/4885 |
| US-12195449-B2 | 3-[(1H-pyrazol-r-yl)oxy]pyrazin-2-amine compounds as HPK1 inhibitor and use thereof | HIPK1, HIPK3, HIPK2 | DDB1 1570/4885CRBN 2883/4885GPR119 413/4885 |
| US-20250236610-A1 | 3-[(1H-PYRAZOL-4-YL)OXY]PYRAZIN-2-AMINE COMPOUNDS AS HPK1 INHIBITOR AND USE THEREOF | HIPK1, HIPK3, HIPK2 | DDB1 1526/4885CRBN 2913/4885GPR119 431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.